scholarly journals PNS137 Do European Health Technology Assessment Bodies Use Multicriteria Decision Analysis to Support Payer's Pricing and Reimbursement Decisions? a Description of Current Practice Using the Evidem Framework

2020 ◽  
Vol 23 ◽  
pp. S663-S664
Author(s):  
D. Elvira ◽  
C. Pontes ◽  
M. Obach
Keyword(s):  
Decision Analysis ◽  
Health Technology Assessment ◽  
Technology Assessment ◽  
Current Practice ◽  
Health Technology ◽  
Multicriteria Decision Analysis ◽  
Multicriteria Decision ◽  
European Health ◽  
Pricing And Reimbursement

scholarly journals Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward

2019 ◽  
Vol 22 (11) ◽  
pp. 1283-1288 ◽  
Author(s):  
Rob Baltussen ◽  
Kevin Marsh ◽  
Praveen Thokala ◽  
Vakaramoko Diaby ◽  
Hector Castro ◽  
...  
Keyword(s):  
Decision Analysis ◽  
Health Technology Assessment ◽  
Technology Assessment ◽  
Health Technology ◽  
Multicriteria Decision Analysis ◽  
Multicriteria Decision ◽  
The Way

scholarly journals Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis

2020 ◽  
Vol 40 (6) ◽  
pp. 830-845
Author(s):  
Aris Angelis ◽  
Mark Thursz ◽  
Vlad Ratziu ◽  
Alastair O’Brien ◽  
Lawrence Serfaty ◽  
...  
Keyword(s):  
Drug Development ◽  
Decision Analysis ◽  
Health Technology Assessment ◽  
Technology Assessment ◽  
Nonalcoholic Steatohepatitis ◽  
Health Technology ◽  
Value Theory ◽  
Multicriteria Decision Analysis ◽  
Multicriteria Decision ◽  
Value Preferences

Background. The assessment of value along the clinical development of new biopharmaceutical compounds is a challenging task. Complex and uncertain evidence has to be analyzed, considering a multitude of value preferences from different stakeholders. Objective. To investigate the use of multicriteria decision analysis (MCDA) to support decision making during drug development while considering payer and health technology assessment (HTA) value concerns, by applying the Advance Value Framework in nonalcoholic steatohepatitis (NASH) and testing for the consistency of the results. Design. A multiattribute value theory methodology was applied and 2 rounds of decision conferences (DCs) were organized in 3 countries (England, France, and Germany), with the participation of national key experts and stakeholders using the MACBETH questioning protocol and algorithm. A total of 51 health care professionals, patient advocates, and methodologists, including (ex-) committee members or assessors from national HTA bodies, participated in 6 DCs in the study countries. Target Population. NASH patients in fibrosis stages F2 to 3 were considered. Interventions. The value of a hypothetical product profile was assessed against 3 compounds under development using their phase 2 results. Outcome Measures. DC participants’ value preferences were elicited involving criteria selection, options scoring, and criteria weighting. Results. Highly consistent valuation rankings were observed in all DCs, always favoring the same compound. Highly consistent rankings of criteria clusters were observed, favoring therapeutic benefit criteria, followed by safety profile and innovation level criteria. Limitations. There was a lack of comparative treatment effects, early evidence on surrogate endpoints was used, and stakeholder representativeness was limited in some DCs. Conclusions. The use of MCDA is promising in supporting early HTA, illustrating high consistency in results across countries and between study rounds.

scholarly journals Description of the use of Multicriteria to Support Pricing and Reimbursement Decisions by European Health Technology Assessment Bodies.

2021 ◽  
Author(s):  
David Elvira ◽  
Mercè Obach ◽  
Caridad Pontes
Keyword(s):  
Health Technology Assessment ◽  
Technology Assessment ◽  
Health Technology ◽  
Assessment Tools ◽  
Assessment Model ◽  
Reference Framework ◽  
Specific Advice ◽  
European Health ◽  
Pricing And Reimbursement ◽  
Assessment Strategies

Abstract BackgroundHeterogeneity in drug access throughout Europe may be influenced by differences in drug-assessment strategies. The EUnetHTA’s assessment core model (EUnetHTA-core) and the EVIDEM’s multicriteria framework are reference methodologies in this context, the latter including a wider compromise between non-contextual and contextual criteria. Compliance of 37 European Health Technology Assessment bodies (HTAb) with EUnetHTA-core has been reported, but the use of EVIDEM by this HTAb is still unknown.ObjectiveTo describe the uptake and use of multicriteria approaches to evaluate drug value by European HTAb using EVIDEM as reference framework. MethodsMulticriteria framework was obtained based on EVIDEM model. The criteria used for drug appraisal by HTAb was extracted from the EUnetHTA report, and completed through search of websites, publications and HTAb reports. Use of EVIDEM assessment model in 37 European HTAb has been described semi-quantitatively and summarized using an alignment heatmap.ResultsAligned, medium or misaligned profiles were seen for 24,3%, 51,4% and 24,3% of HTAb when matching to EVIDEM dimensions and criteria was considered. HTAb with explicit responsibilities in providing specific advice on reimbursement showed more aligned profiles on contextual and non-contextual dimensions. ConclusionsMost of the 37 European HTAb have room to broaden their contextual assessment tools, especially when social and medical perception of need requires to be explicit to support payer’s decision on reimbursement.

Sign in / Sign up

Export Citation Format

Share Document